Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Operating Expenses (2024 - 2026)

Maze Therapeutics' Operating Expenses history spans 3 years, with the latest figure at $46.6 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 31.5% to $46.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $154.1 million, a 31.33% increase, with the full-year FY2025 number at $142.9 million, up 30.01% from a year prior.
  • Operating Expenses hit $46.6 million in Q1 2026 for Maze Therapeutics, up from $38.1 million in the prior quarter.
  • Over the last five years, Operating Expenses for MAZE hit a ceiling of $46.6 million in Q1 2026 and a floor of $25.4 million in Q2 2024.
  • Historically, Operating Expenses has averaged $33.3 million across 3 years, with a median of $33.0 million in 2025.
  • The widest YoY moves for Operating Expenses: up 43.34% in 2025, down 23.33% in 2025.
  • Tracing MAZE's Operating Expenses over 3 years: stood at $29.7 million in 2024, then increased by 28.03% to $38.1 million in 2025, then grew by 22.32% to $46.6 million in 2026.
  • Business Quant data shows Operating Expenses for MAZE at $46.6 million in Q1 2026, $38.1 million in Q4 2025, and $33.0 million in Q3 2025.